Company: UP
Filing Date: 2025-12-19
Form Type: 8-K
Source: 0001628280-25-058340
Chunk: 1

Company: Wheels Up Experience Inc.
Filing Date: 2025-12-19
Form: 8-K
Item: Item 3.01
Chunk 1
---
 in the number of authorized shares of Common Stock by a ratio corresponding to the reverse stock split ratio (together, the “ Potential Reverse Split”). Additional details about the Proposal, including risks related to the Potential Reverse Split, are included under the caption “ Proposal No. 7 - Reverse Stock Split and Authorized Share Reduction” in the Company’s definitive proxy statement on Schedule 14A filed with the U. S. Securities and Exchange Commission (the “ SEC”) on April 24, 2025.

On December 19, 2025, the Company notified the NYSE that, unless the Company otherwise regains compliance with Section 802.01C using other available methods, it intends to regain compliance with Section 802.01C by completing the Potential Reverse Split with sufficient time before the end of the Cure Period to cure the noted deficiency. The Potential Reverse Split would require the approval of the Board, which has been authorized to approve the Potential Reverse Split at any time prior to the 2026 Annual Meeting, and be publicly announced by the Company following any such Board approval. However, the Board has not approved the Potential Reverse Split as of the date of this Current Report. If the Board approves, and the Company completes, the Potential Reverse Split with respect to the Common Stock during the Cure Period, the Company anticipates that it would regain compliance with Section 802.01C upon satisfaction of the Cure Conditions. The Company may also consider various other available options to regain compliance with Section 802.01C.

The Notice has no immediate impact on the listing of the Common Stock on the NYSE, which will continue to be listed and trade on the NYSE under the symbol “ UP”, subject to the Company’s compliance with the other NYSE continued listing standards. The symbol for the Common Stock will have an added designation of “. BC” to indicate “below compliance” with the NYSE’s continued listing standards, which will be removed if the Company regains compliance. In addition, the Notice does not affect the Company’s reporting requirements under applicable law and the rules and regulations promulgated by the SEC or result in an event of default under any of the Company’s material debt agreements or other arrangements. There can be no assurance that the Company will be able to regain compliance with Section 802.01C or will not otherwise be delisted from the NYSE prior to the end of the Cure Period.

Item 7.01 Regulation FD Disclosure.